Integrated Molecular and Cellular Drivers of Alveologenesis
肺泡发生的综合分子和细胞驱动因素
基本信息
- 批准号:10637764
- 负责人:
- 金额:$ 72.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-05-20 至 2028-04-30
- 项目状态:未结题
- 来源:
- 关键词:AblationAgonistAlveolarAlveolusArchitectureBlood capillariesBronchopulmonary DysplasiaCapillary Endothelial CellCell Differentiation processCell NucleusCell ProliferationCellsChromatinCollagenDataDevelopmentDistalEndothelial CellsEndotoxinsEpithelial CellsEpitheliumExtracellular MatrixExtracellular Matrix ProteinsFluorescent in Situ HybridizationFour-dimensionalGenerationsGenetic TranscriptionGoalsGrowthHealthHumanHyperoxiaImageImmunofluorescence ImmunologicImpairmentInflammationInjuryKnowledgeLamininLibrariesLightLungMesenchymalMicroscopyModelingMolecularMolecular TargetMyofibroblastPathway interactionsPatternPhenotypePregnancyPremature BirthPremature InfantProcessProductionProliferatingPublishingRegulationReporterResolutionRoleSamplingSignal PathwaySignal TransductionSliceStructureTestingTherapeuticTimeTransgenic OrganismsVisualizationWNT Signaling Pathwayalveolar epitheliumantagonistcapillary bedcell motilitydelivery complicationsexperimental studyextracellularhigh riskin vivoinhibitorinnovationlung developmentlung injurymultiple omicsneonatal exposureneonatal injuryneonatal lung injuryneonatal miceneonatenew growthnovel strategiesoverexpressionpostnatalpulmonary functionreal-time imagesrecruitresponserestorationscaffoldsecond harmonicspatial relationshipspatiotemporaltemporal measurementtranscriptome sequencingtranscriptomics
项目摘要
PROJECT SUMMARY
Neonates born during the saccular stage of lung development (23-32 wks gestation) are at highest risk for
bronchopulmonary dysplasia (BPD), a leading preterm birth complication. The mechanisms underlying this
vulnerability are poorly defined, a knowledge gap we consider foundational to the lack of curative BPD
therapies. To understand the irreversibility of arrested alveologenesis in BPD, we require a refined,
mechanistic understanding of the normal saccular to alveolar transition. Our preliminary data from 4-
dimensional live imaging and single-cell transcriptomics support a new model of alveologenesis in which
myofibroblast ring structures support the extrusion of AT2s (alveolar type 2 cells) followed by their
differentiation into AT1s (alveolar type 1 cells). According to our model, mature AT1s produce ECM proteins
and other factors that recruit specialized endothelial cells to become the alveolar capillary bed. Sequential,
spatiotemporally restricted signaling pathways, including Wnt and BMP, coordinate cell movement,
proliferation, and architecture. We have developed a neonatal injury model with a phenotype of impaired
alveologenesis that is relevant to human BPD by exposing neonatal mice to hyperoxia and inflammation during
the saccular stage. Our preliminary data from this model associate overexpression of Wnt5A/Wnt11 with
impaired alveologenesis. Post-injury deficits include decreased BMP production and activity in alveolar
epithelial cells and impaired AT2 to AT1 cell differentiation and decreased expression of extracellular matrix
(ECM) components by AT1 cells. Based on preliminary and published data, we hypothesize that
alveologenesis involves formation of a ring of myofibroblasts that express Wnt5a and Wnt 11 to drive AT2
proliferation and promote extrusion through the ring. Subsequent epithelial BMP production down-regulates
Wnt, promoting AT2 to AT1 differentiation and generation of an extracellular scaffold for capillary assembly.
Injury dysregulates Wnt and Bmp signaling, perturbing the precise spatiotemporal patterning during this critical
timeframe and resulting in arrested alveologenesis and long-term functional deficits. We will test this
hypothesis in the following specific aims: 1) Define the role of myofibroblast Wnt expression in regulating
AT2 proliferation and alveolar development; 2) Characterize mechanisms by which BMP signaling
regulates AT2-to-AT1 cell differentiation; 3) Determine the mechanisms whereby nascent AT1 cells
generate a scaffold for the developing alveolus. Successful completion of this proposal is anticipated to
transform our understanding of alveologenesis, identifying new molecular targets to promote post-injury
alveolar restoration and the optimal time windows for deployment of such newly directed therapies.
项目摘要
在肺发育的囊状期(妊娠23-32周)出生的新生儿,
支气管肺发育不良(BPD),一种主要的早产并发症。这背后的机制
脆弱性定义不清,我们认为这是缺乏治疗性BPD的基础知识差距
治疗为了了解BPD中肺泡形成受阻的不可逆性,我们需要一个精炼的,
对正常囊泡到肺泡过渡的机械理解。我们的初步数据来自4-
三维活体成像和单细胞转录组学支持一种新的肺泡发生模型,
肌成纤维细胞环结构支持AT 2(肺泡2型细胞)的挤出,然后它们的细胞被释放。
分化为AT 1(肺泡1型细胞)。根据我们的模型,成熟的AT 1产生ECM蛋白,
以及其他招募特化内皮细胞成为肺泡毛细血管床的因素。连续的,
包括Wnt和BMP在内的时空受限的信号传导途径,协调细胞运动,
扩散和架构。我们已经建立了一个新生儿损伤模型,
肺泡发生与人BPD相关,通过将新生小鼠暴露于高氧和炎症,
囊状阶段我们从该模型获得的初步数据将Wnt 5A/Wnt 11的过表达与
肺泡形成受损损伤后的缺陷包括肺泡上皮细胞中BMP的产生和活性降低,
上皮细胞和AT 2向AT 1细胞分化受损以及细胞外基质表达减少
(ECM)AT 1细胞。根据初步和已发表的数据,我们假设,
肺泡发生涉及表达Wnt 5a和Wnt 11以驱动AT 2的成肌纤维细胞环的形成
增殖并促进通过环的挤出。随后的上皮BMP产生下调
Wnt,促进AT 2向AT 1分化和产生用于毛细血管组装的细胞外支架。
损伤使Wnt和Bmp信号传导失调,扰乱了这一关键过程中的精确时空模式。
时间范围内,并导致肺泡生成停滞和长期功能缺陷。我们将测试这个
1)确定肌成纤维细胞Wnt表达在调节肌成纤维细胞增殖中的作用。
AT 2增殖和肺泡发育; 2)表征BMP信号传导的机制,
调节AT 2-到-AT 1细胞分化; 3)确定新生AT 1细胞
为发育中的肺泡提供支架。成功完成这一提案预计将
改变我们对肺泡发生的理解,确定新的分子靶点,
牙槽修复和部署这种新定向疗法的最佳时间窗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jennifer MalcolmSrygley Sucre其他文献
Jennifer MalcolmSrygley Sucre的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jennifer MalcolmSrygley Sucre', 18)}}的其他基金
Wnt Signaling in Bronchopulmonary Dysplasia
支气管肺发育不良中的 Wnt 信号转导
- 批准号:
10226945 - 财政年份:2019
- 资助金额:
$ 72.89万 - 项目类别:
Wnt Signaling in Bronchopulmonary Dysplasia
支气管肺发育不良中的 Wnt 信号转导
- 批准号:
10458630 - 财政年份:2019
- 资助金额:
$ 72.89万 - 项目类别:
Wnt Signaling in Bronchopulmonary Dysplasia
支气管肺发育不良中的 Wnt 信号转导
- 批准号:
10671760 - 财政年份:2019
- 资助金额:
$ 72.89万 - 项目类别:
相似国自然基金
GLP-1受体激动剂通过肠道菌群代谢产物SCFAs抑制PI3K/AKT/NF-κB信号通路抑制糖尿病肾病机制进展研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
胰高血糖素样肽-1受体激动剂通过内皮UCP2减轻缺血性脑卒中后血脑屏障的破坏
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于靶点结构的新型HsClpP小分子激动
剂的设计、合成及生物活性研究
- 批准号:
- 批准年份:2025
- 资助金额:10.0 万元
- 项目类别:省市级项目
基于I型干扰素免疫调控机制促进结直肠肿瘤“冷-热”转换的STING激动剂的设计与发现
- 批准号:2025JJ70449
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于深度感知网络探讨GLP-1RA对肥胖相关认知障碍的保护作用及神经重塑机制研究
- 批准号:2025JJ60835
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
新型Nrf2激动剂Bitopertin对川崎病心肌细胞铁死亡的保护作用及机制研究
- 批准号:JCZRLH202500755
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
CD40激动剂介导巨噬细胞M1极化激活放疗旁观者效应的研究
- 批准号:JCZRYB202500454
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
新型IP受体激动剂的设计、合成及活性筛选研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
GLP-1/GIP/PPAR多靶点激动剂的分子构建及抗非酒精性脂肪肝病合并2型糖尿病作用研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
FGF23部分激动剂的药物设计及其治疗急性肾损伤的药理作用机制研究
- 批准号:DG25H300001
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 72.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 72.89万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 72.89万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 72.89万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 72.89万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 72.89万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 72.89万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 72.89万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 72.89万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 72.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)